TNON Stock Price, Tenon Medical, Inc. Quote, Chart

Market Summary

USD0.85-0.03

Market Closed

-3.41%

TNON Stock Price

View Fullscreen

TNON RSI Chart

TNON Valuation

Market Cap

3.2M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.99

Price/Free Cashflow

-0.29

TNON Price/Sales (Trailing)

TNON Profitability

Operating Margin

54.70%

Return on Equity

-395.34%

Return on Assets

-178.64%

Free Cashflow Yield

-345.26%

TNON Fundamentals

TNON Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

66.05%

Rev. Growth (Qtr)

-11.01%

TNON Earnings

Earnings (TTM)

-14.3M

Earnings Growth (Yr)

25.96%

Earnings Growth (Qtr)

-14.1%

Breaking Down TNON Revenue

Last 7 days

-4.5%

Last 30 days

10.4%

Last 90 days

-30.3%

Trailing 12 Months

-52.5%

How does TNON drawdown profile look like?

TNON Financial Health

Current Ratio

2.63

TNON Investor Care

Shares Dilution (1Y)

231.47%

Diluted EPS (TTM)

-6.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.2M	0	0	0
2023	1.1M	1.7M	2.4M	2.9M
2022	216.0K	329.0K	467.0K	691.0K
2021	0	0	0	160.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tenon Medical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 27, 2023	ginn richard	sold (taxes)	-4,604	2.0001	-2,302	chief technology officer
Nov 27, 2023	foster steven m	sold (taxes)	-1,802	2.0001	-901	ceo and president
Nov 22, 2023	van dick steven m	acquired	3,074	2.02	1,522	chief financial officer
Nov 22, 2023	ginn richard	acquired	15,182	2.02	7,516	chief technology officer
Nov 22, 2023	foster steven m	acquired	7,320	2.02	3,624	ceo and president
Jun 14, 2023	van dick steven m	bought	13,650	0.273	50,000	chief financial officer
May 23, 2023	ginn richard	sold	-81,887	1.26	-64,990	chief technology officer
May 23, 2023	foster steven m	sold	-35,016	1.26	-27,791	ceo and president
May 22, 2023	ferrari richard	acquired	147,906	1.62	91,300	-
May 22, 2023	fischer frank m	acquired	10,055	1.62	6,207	-

Which funds bought or sold TNON recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-7.00	10.00	-%
May 15, 2024	Cable Car Capital LLC	unchanged	-	-10,774	29,882	0.04%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-90.00	-3,774	10,466	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	54.17	-590	7,484	-%
May 15, 2024	Lee Financial Co	sold off	-100	-5,529	-	-%
May 15, 2024	Royal Bank of Canada	added	205	1,000	1,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	72.61	844	3,986	-%
May 14, 2024	TMD Wealth Management, LLC	unchanged	-	219,094	301,703	0.07%
May 14, 2024	TMD Wealth Management, LLC	unchanged	-	-270,148	407,367	0.10%
May 14, 2024	Qube Research & Technologies Ltd	new	-	95.00	95.00	-%

Are Funds Buying or Selling TNON?

Are funds buying TNON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNON

No. of Funds

Unveiling Tenon Medical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2024	tmd wealth management, llc	25.40%	941,888	SC 13G
Feb 14, 2024	tmd wealth management, llc	31.56%	2,984,262	SC 13G/A
Sep 13, 2023	tmd wealth management, llc	32.58%	8,712,362	SC 13G/A

Recent SEC filings of Tenon Medical, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 10, 2024	POS AM	POS AM
May 10, 2024	S-1	Initial Public Offering
May 08, 2024	8-K	Current Report
May 07, 2024	SC TO-I/A	SC TO-I/A
Apr 16, 2024	SC 13G	Major Ownership Report
Apr 08, 2024	SC TO-I	SC TO-I
Apr 01, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	3	Insider Trading

Tenon Medical, Inc. News

Latest updates

Tenon Medical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-11.0%	719	808	944	743	433	277	208	135	71.00	53.00	70.00	22.00	15.00
Cost Of Revenue	0%	249	249	409	549	480	484	302	271	275	17.00	18.00	9.00	11.00
Gross Profit	-15.9%	470	559	535	194	-47.00	-207	-94.00	-136	-204	36.00	52.00	13.00	4.00
Operating Expenses	7.5%	3,976	3,700	3,913	4,516	4,839	7,721	3,168	5,320	1,875	2,598	2,149	1,626	193
S&GA Expenses	2.9%	1,381	1,342	1,527	1,883	2,026	4,969	645	1,943	276	668	556	913	4.00
R&D Expenses	-3.2%	669	691	737	901	834	812	797	657	562	793	601	237	87.00
Interest Expenses	100.0%	34.00	17.00	4.00	-	-	-8.00	-	88.00	274	281	267	62.00	11.00
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	1.00	-
Net Income	-14.1%	-3,576	-3,134	-3,332	-4,285	-4,830	-7,905	-3,171	-5,488	-2,353	-2,842	-2,341	-1,665	-200
Net Income Margin	16.2%	-4.46*	-5.32*	-8.49*	-12.16*	-20.32*	-27.38*	-29.67*	-39.59*	-42.60*	-44.05*	-	-	-
Free Cashflow	-2.6%	-2,395	-2,335	-3,210	-3,304	-3,660	-3,986	-3,490	-2,804	-2,592	-1,774	-1,429	-1,029	-162

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	26.4%	8,020	6,345	7,318	9,855	7,629	11,089	14,937	18,131	7,145	9,272
Current Assets	53.0%	5,951	3,889	4,963	7,929	5,841	9,347	13,665	16,858	5,425	7,672
Cash Equivalents	80.7%	4,388	2,428	3,371	5,852	3,179	2,129	3,153	7,875	4,677	2,917
Inventory	14.1%	632	554	474	570	416	415	810	628	602	188
Net PPE	3.3%	993	961	956	945	852	793	294	241	219	101
Liabilities	-21.0%	4,396	5,567	4,801	8,952	5,155	4,837	1,990	3,018	16,241	16,185
Current Liabilities	-28.0%	2,262	3,140	3,085	6,866	2,752	2,530	1,266	2,236	15,402	15,274
Shareholder's Equity	365.8%	3,624	778	2,517	903	2,474	6,252	12,947	15,113	-	-20,552
Retained Earnings	-6.5%	-58,649	-55,073	-51,939	-48,607	-44,322	-39,492	-31,587	-28,416	-22,928	-20,575
Additional Paid-In Capital	5.5%	58,969	55,894	54,556	49,560	46,873	45,843	44,691	43,657	282	113
Shares Outstanding	43.3%	3,727	2,600	2,471	2,162	1,125	1,124	1,124	1,124	99.00	99.00
Float	-	-	-	-	4,892	-	-	-	17,509	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-2.6%	-2,338	-2,278	-3,153	-3,176	-3,576	-3,385	-3,413	-2,763	-2,464	-1,690	-1,411	-1,029	-162
Share Based Compensation	3.8%	1,018	981	1,070	1,054	1,040	1,142	1,034	552	169	169	143	61.00	4.00
Cashflow From Investing	-29.3%	-119	-92.00	436	1,129	4,669	2,339	-1,317	-8,182	4,276	3,375	-7,879	-	-
Cashflow From Financing	218.8%	4,371	1,371	266	4,707	-42.00	-25.00	-	14,193	-54.00	-179	3,786	7,892	-30.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TNON Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 719	$ 433
Cost of revenue	249	480
Gross Profit (Loss)	470	(47)
Operating Expenses
Research and development	669	834
Sales and marketing	1,381	2,026
General and administrative	1,926	1,979
Total Operating Expenses	3,976	4,839
Loss from Operations	(3,506)	(4,886)
Other (Expense) Income, net
Gain on investments	27	56
Interest expense	(34)
Other expense	(63)
Total Other (Expense) Income, net	(70)	56
Net Loss	$ (3,576)	$ (4,830)
Net Loss Per Share of Common Stock
Basic (in Dollars per share)	$ (1.25)	$ (4.3)
Weighted Average Shares of Common Stock Outstanding
Basic (in Shares)	2,853	1,124
Consolidated Statements of Comprehensive Loss:
Net loss	$ (3,576)	$ (4,830)
Unrealized gain on investments		13
Foreign currency translation adjustment	46	(1)
Total Comprehensive Loss	$ (3,530)	$ (4,818)

TNON Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,388	$ 2,428
Accounts receivable	571	518
Inventory	632	554
Prepaid expenses	360	389
Total current assets	5,951	3,889
Fixed assets, net	993	961
Deposits	51	51
Operating lease right-of-use asset	586	646
Deferred offering costs	439	798
TOTAL ASSETS	8,020	6,345
Current liabilities:
Accounts payable	266	433
Accrued expenses	941	808
Current portion of accrued commissions	792	470
Current portion of operating lease liability	263	256
Convertible notes payable and accrued interest, net of debt discount of $0 and $77 at March 31, 2024 and December 31, 2023, respectively		1,173
Total current liabilities	2,262	3,140
Accrued commissions, net of current portion	1,774	1,999
Operating lease liability, net of current portion	360	428
Total liabilities	4,396	5,567
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value; 130,000,000 shares authorized at March 31, 2024 and December 31, 2023; 3,726,974 and 2,600,311 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	3
Additional paid-in capital	58,969	55,894
Accumulated deficit	(58,649)	(55,073)
Accumulated other comprehensive loss		(46)
Total stockholders’ equity	3,624	778
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	8,020	6,345
Series A Convertible Preferred Stock
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at March 31, 2024 and December 31, 2023; 256,968 and 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	$ 3,300

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as stabilizes and transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.

CEO	Mr. Steven M. Foster
WEBSITE	tenonmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	22

Tenon Medical, Inc. Frequently Asked Questions

What is the ticker symbol for Tenon Medical, Inc.? What does TNON stand for in stocks?

TNON is the stock ticker symbol of Tenon Medical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenon Medical, Inc. (TNON)?

As of Fri May 17 2024, market cap of Tenon Medical, Inc. is 3.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNON stock?

You can check TNON's fair value in chart for subscribers.

What is the fair value of TNON stock?

You can check TNON's fair value in chart for subscribers. The fair value of Tenon Medical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tenon Medical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tenon Medical, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNON is over valued or under valued. Whether Tenon Medical, Inc. is cheap or expensive depends on the assumptions which impact Tenon Medical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNON.

What is Tenon Medical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TNON's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 0.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNON PE ratio will change depending on the future growth rate expectations of investors.